EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aerie Pharmaceuticals's enterprise value is $918.1 Mil.
Aerie Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $-3.1 Mil. Therefore, Aerie Pharmaceuticals's EV-to-EBITDA for today is -298.68.
The historical rank and industry rank for Aerie Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
AERI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -298.68 Med: -7.63 Max: -3.06
Current: -298.68
During the past 11 years, the highest EV-to-EBITDA of Aerie Pharmaceuticals was -3.06. The lowest was -298.68. And the median was -7.63.
AERI's EV-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 14.03
vs AERI: -298.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Aerie Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for Aerie Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aerie Pharmaceuticals's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Aerie Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aerie Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aerie Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aerie Pharmaceuticals's EV-to-EBITDA falls into.
Aerie Pharmaceuticals's current Enterprise Value is $918.1 Mil.
Aerie Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Aerie Pharmaceuticals's PE Ratio for today is calculated as:
Aerie Pharmaceuticals's share price for today is $15.25.
Aerie Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Aerie Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AERI has been successfully added to your 